Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab

Fingolimod is used for the treatment of multiple sclerosis (MS) and targets receptors for the bioactive sphingolipid sphingosine-1-phosphate. Whether fingolimod or other MS therapies conversely affect plasma concentrations of sphingolipids has, however, not yet been analyzed. Herein, we quantified 1...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Florian Ottenlinger, Christoph Alexander Mayer, Nerea Ferreirós, Yannick Schreiber, Anja Schwiebs, Katrin Schmidt, Hanns Ackermann, Josef Pfeilschifter, Heinfried H. Radeke
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Frontiers Media S.A. 2016-11-01
Reeks:	Frontiers in Pharmacology
Onderwerpen:	Ceramides Interferon-beta Multiple Sclerosis Sphingolipids fingolimod natalizumab
Online toegang:	http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00412/full
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!